The diagnosis of diseases based on immunosensors have been objective of research in the last years, providing an improvement for a rapid detection, high sensitivity, precision, accuracy, specificity and resolution. Areas of progress such as analytical technologies, interpretation and standardization has been done for common biomarkers. However, years of research and development of a functional immunosensor with an unusual biomarker require further investigation to be optimized in any aspect. Recent development of biosensors to diagnose nervous system diseases, such as immunosensors for multiple sclerosis, has been the object of study in the past 10 years to improve common in vitro diagnostic methods such as enzyme-linked immunosorbent assays (ELISA) on cerebrospinal fluid (CSF), showing a big opportunity for further diagnostic optimization. The aim of this review is to show a report on the development of in vitro immunosensors for multiple sclerosis diagnosis until today, with the particular focus on monitoring analyte concentration levels on cerebrospinal fluid and serum as a contribution and improvement to current diagnostic methods.

近年来，基于免疫传感器的疾病诊断一直是研究的目标，为快速检测，高灵敏度，精密度，准确性，特异性和分辨率提供了改进。常见生物标志物的分析技术，解释和标准化等进展领域已经完成。然而，多年来对具有不寻常生物标志物的功能性免疫传感器的研究和开发需要进一步研究以在任何方面进行优化。在过去的十年中，用于诊断神经系统疾病的生物传感器（例如用于多发性硬化症的免疫传感器）的最新开发一直是研究的目标，以改进常见的体外诊断方法，例如对脑脊液（CSF）进行酶联免疫吸附测定（ELISA） ），这为进一步诊断优化提供了巨大的机会。